Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	$ 26,087.7	$ 29,602.5
Product rights and licenses
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	26,084.5	29,598.7
Product rights and licenses | Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	14,313.6	17,514.5
Product rights and licenses | Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	6,115.0	4,385.0
Product rights and licenses | JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	1,495.8	2,803.2
Product rights and licenses | Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	4,160.1	4,896.0
Product rights and licenses | Brands
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	21,146.0	22,216.1
Product rights and licenses | Brands | Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	10,066.6	10,988.1
Product rights and licenses | Brands | Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	6,102.9	4,372.3
Product rights and licenses | Brands | JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	1,174.8	2,377.0
Product rights and licenses | Brands | Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	3,801.7	4,478.7
Product rights and licenses | Complex Gx and Biosimilars
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	228.3	274.8
Product rights and licenses | Complex Gx and Biosimilars | Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	226.8	272.5
Product rights and licenses | Complex Gx and Biosimilars | Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	0.0	0.0
Product rights and licenses | Complex Gx and Biosimilars | JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	1.5	2.3
Product rights and licenses | Complex Gx and Biosimilars | Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	0.0	0.0
Product rights and licenses | Generics
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	4,710.2	7,107.8
Product rights and licenses | Generics | Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	4,020.2	6,253.9
Product rights and licenses | Generics | Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	12.1	12.7
Product rights and licenses | Generics | JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	319.5	423.9
Product rights and licenses | Generics | Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	$ 358.4	$ 417.3